{Reference Type}: Journal Article
{Title}: [Monoclonal gammopathy of undetermined significance and evolution to myeloma: Experience in 153 patients].
{Author}: López Gómez JM;Sacristán Enciso B;Fernández-Cavada Pollo MJ;Bueno García V;Gómez Vera S;
{Journal}: Semergen
{Volume}: 47
{Issue}: 7
{Year}: Oct 2021
暂无{DOI}: 10.1016/j.semerg.2021.05.011
{Abstract}: <B>BACKGROUND: </B>Based on risk factors, the Mayo Clinic Multiple Myeloma Group (MCMMG) established a model of progression from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) at 20 years. It is also described that MGUS with a progressive increase of monoclonal protein (M-protein) and/or immunoparesis (IMP) may be more predisposed to progress to myeloma. Our objective was to make a review of MGUS, to see how those who presented IMP and/or progression of their M-protein, contrasting them with MGUS that presented intermediate/high and high risk according to MCMMG.<BR><B>UNASSIGNED: </B>A review of the MGUS objectified during the realization of a serum proteinogram (SPEP) was carried out during 2010-2014, in our area. Serum immunoglobulins, serum immunofixation (IFs), and serum free light chain ratio (FLCr) were determined for all MGUS.<BR><B>RESULTS: </B>Of the 153 MGUS that are followed up for 4 years, 6 progress to MM. Of these 6 MM, 5 progress from MGUS with intermediate/high risk taking into account the MCMMG. Of these 5, 3 have IMP or progression of their M-protein. 2 present IMP plus progression of their M-protein. The sixth MM evolves from a MGUS without any risk factor, but with progression of its M-protein plus IMP.<BR><B>CONCLUSIONS: </B>IMP and/or M-protein progression are important risk factors to be taken into account in the MGUS, in the first years after diagnosis, due to their possible evolution to MM.